Study Summary
This trial is testing if a combination of two drugs, rucaparib and enzalutamide, is better than enzalutamide alone for treating men with prostate cancer that has spread and become resistant to testosterone-deprivation therapy.
- Castration-resistant Prostate Cancer
- Stage IVB Prostate Cancer
- Stage IV Prostate Cancer
- Stage IVA Prostate Cancer
- Prostate Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 10 Secondary · Reporting Duration: Up to 5 years post treatment
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Arm II (enzalutamide, placebo)
1 of 2
Arm I (enzalutamide, rucaparib)
1 of 2
Active Control
Experimental Treatment
1002 Total Participants · 2 Treatment Groups
Primary Treatment: Rucaparib camsylate · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Male Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is Rucaparib camsylate a safe prescription medication?
"3." - Anonymous Online Contributor
In how many different medical facilities is this research project being conducted currently?
"There are 100 patients enrolling in this clinical trial at the West Michigan Cancer Center in Kalamazoo, Saint Joseph Mercy Brighton in Brighton, and Spectrum Health at Butterworth Campus in Grand Rapids. There are also 100 other enrollees spread out across different locations." - Anonymous Online Contributor
What is the main therapeutic purpose of Rucaparib camsylate?
"While Rucaparib camsylate is most frequently used to treat breast cancer, it can also help patients manage side effects of radiation therapy and endometrial thinning. It is even effective against stage t2b carcinoma of the prostate." - Anonymous Online Contributor
Can patients sign up for this clinical trial at this time?
"That is correct, based on the information available clinicaltrials.gov this study is looking for 1002 patients at 100 different locations and is still actively recruiting as of 9/25/2022." - Anonymous Online Contributor
How many people have been signed up to participate in this clinical trial?
"That is accurate, the clinicaltrials.gov website shows that this trial is open and looking for candidates. The listing appeared on 2/19/2021 and was updated as recently as 9/25/2022. They are hoping to 1002 people across 100 different locations." - Anonymous Online Contributor
Have other similar trials been conducted in the past?
"Rucaparib camsylate has been researched since 2000 when it was first trialed by AstraZeneca. The Phase 3 drug approval happened in light of the successful 600 person study. Today, there are 245 active studies involving Rucaparib camsylate being conducted across 63 countries and 2316 cities" - Anonymous Online Contributor
What goals does this research aim to achieve?
"The aim of this study, which will be conducted over a period of up to 5 years after treatment, is to assess overall survival rates. Secondary outcomes include the incidence of adverse events as measured by the National Cancer Institute's Common Toxicity Criteria, prostate specific antigen (PSA) response rates, and radiographic progression-free survival within HRRm status. Treatment arm comparisons will be made using chi-square tests and log-rank tests, with median times per treatment arm being reported." - Anonymous Online Contributor
What similar investigations has Rucaparib camsylate been a part of in the past?
"Rucaparib camsylate is being studied in 245 different clinical trials. Of those, 71 are Phase 3 trials. Many of the studies related to Rucaparib camsylate originate from Lincoln, Nebraska; however, there are 14809 total locations running these medical trials." - Anonymous Online Contributor